numer
patholog
state
includ
cancer
autoimmun
diseas
viralbacteri
infect
often
attribut
uncontrol
dna
replic
inhibit
essenti
biolog
process
provid
obviou
therapeut
target
diseas
logic
target
dna
polymeras
enzym
respons
catalyz
addit
mononucleotid
grow
polym
use
dna
rna
templat
guid
direct
incorpor
event
review
provid
summari
therapeut
agent
target
polymeras
activ
discuss
biolog
function
mechan
polymeras
first
provid
illustr
strategi
therapeut
intervent
well
ration
design
variou
nucleosid
analog
inhibit
variou
polymeras
associ
viral
infect
cancer
develop
nucleosid
nonnucleosid
inhibitor
antivir
agent
discuss
particular
emphasi
mechan
action
structureact
relationship
toxic
mechan
resist
addit
commonli
use
anticanc
agent
describ
illustr
similar
differ
associ
variou
nucleosid
analog
therapeut
agent
final
new
therapeut
approach
discuss
includ
inhibit
select
polymeras
involv
dna
repair
andor
transles
dna
synthesi
anticanc
agent
dna
replic
process
duplic
dna
gener
two
copi
organ
genet
inform
figur
complex
biolog
process
catalyz
dna
polymeras
add
mononucleotid
grow
primer
use
nucleic
acid
templat
guid
direct
incorpor
event
figur
dna
replic
absolut
essenti
prolifer
surviv
form
life
rang
simpl
virus
bacteria
complex
organ
includ
human
import
dna
replic
often
highlight
varieti
patholog
state
result
dysfunct
andor
unregul
activ
exampl
certain
genet
diseas
ataxia
telangiectasia
associ
gener
mutat
caus
decreas
fidel
replic
hyperprolif
diseas
cancer
autoimmun
condit
viralbacteri
infect
associ
uncontrol
case
promutagen
dna
replic
major
goal
biomed
scienc
develop
therapeut
agent
combat
patholog
state
outlin
figur
sever
strategi
current
use
inhibit
dna
replic
one
approach
use
dna
damag
agent
step
modifi
nucleic
acid
longer
act
effect
substrat
dna
polymeras
exampl
includ
chemotherapeut
agent
temozolomid
cisplatin
modifi
composit
structur
dna
inhibit
dna
synthesi
prevent
cellular
prolifer
effect
util
typic
limit
sever
side
effect
caus
nonselect
kill
cancer
healthi
cell
addit
potenti
induc
mutagen
event
actual
acceler
diseas
develop
anoth
strategi
modul
activ
individu
enzym
involv
dna
replic
step
agent
etoposid
inhibit
activ
topoisomeras
enzym
resolv
knot
dna
form
replic
inhibit
enzym
caus
apoptosi
creat
singleand
doublestrand
dna
break
interrupt
continu
dna
synthesi
third
approach
includ
reduc
avail
dntp
build
block
dna
synthesi
step
inhibit
enzym
involv
nucleotid
metabol
antimetabolit
methotrex
hydroxyurea
reduc
nucleotid
pool
indirectli
hinder
dna
synthesi
perhap
direct
approach
howev
use
nucleosid
analog
azt
fludaribin
target
enzymat
activ
dna
polymeras
workhors
dna
replic
apparatu
step
last
strategi
repres
focu
review
articl
shall
discuss
design
mechan
action
pitfal
associ
variou
nucleosid
analog
use
therapeut
agent
common
hyperprolif
diseas
includ
viral
infect
cancer
describ
nucleosid
analog
act
therapeut
agent
first
necessari
understand
mechan
dna
polymer
perturb
variou
kinet
step
influenc
effect
gener
mechan
appli
prokaryot
eukaryot
dna
polymeras
provid
figur
illustr
intric
biolog
process
occur
via
multipl
mechan
polymeras
bind
dna
prior
bind
dntp
first
point
gener
high
catalyt
effici
fidel
occur
bind
dntp
polymeras
dna
complex
step
bind
affin
k
valu
nucleotid
opposit
correct
pair
partner
gener
k
valu
incorrect
nucleotid
usual
higher
dntp
bind
enzymat
conform
chang
step
propos
align
incom
dntp
precis
geometr
orient
necessari
phosphoryl
transfer
step
conform
chang
step
reflect
inducedfit
mechan
also
impos
discrimin
nucleotid
misinsert
misalign
intermedi
perturb
geometri
polymeras
activ
site
prevent
chemic
step
anoth
point
error
discrimin
occur
phosphoryl
transfer
step
step
may
ratelimit
nucleotid
incorpor
certain
polymeras
regardless
maxim
rate
constant
polymer
denot
k
pol
incorpor
correct
nucleotid
opposit
cognat
partner
gener
rang
sec
thu
rel
low
bind
affin
correct
nucleotid
offset
fast
k
pol
valu
overal
catalyt
effici
k
pol
k
correct
polymer
high
inde
k
pol
k
valu
sec
limit
diffus
control
place
polymeras
within
top
tier
profici
enzym
also
import
emphas
k
pol
k
valu
incorrect
dna
synthesi
ie
misincorpor
datp
opposit
typic
sever
order
magnitud
lower
due
decreas
k
pol
coupl
increas
k
reduct
play
larg
role
mainten
genom
fidel
follow
phosphoryl
transfer
second
conform
chang
step
requir
pyrophosph
releas
step
pyrophosph
pp
releas
polymeras
either
remain
bound
nucleic
acid
substrat
continu
primer
elong
step
dissoci
elong
primer
step
initi
dna
synthesi
anoth
usabl
primer
templat
abil
incorpor
multipl
nucleotid
without
dissoci
dna
defin
process
polymeras
alter
variou
kinet
step
occur
influenc
behavior
polymeras
alter
effect
certain
chemotherapeut
agent
one
exampl
abil
polymeras
revers
polymer
step
figur
step
via
process
known
pyrophosphorolysi
remov
inappropri
incorpor
nucleotid
kinet
step
includ
dntp
bind
step
figur
step
conform
chang
preced
chemistri
figur
step
mechanist
framework
highlight
import
kinet
step
target
inhibit
replic
prevent
prolifer
one
potenti
stage
therapeut
intervent
use
competit
inhibitor
block
dntp
bind
polymeras
activ
site
figur
step
unfortun
develop
revers
inhibitor
bind
tightli
select
dna
polymeras
extraordinarili
difficult
task
much
challeng
aris
promiscu
rel
weak
bind
affin
k
natur
nucleotid
polymeras
furthermor
correct
polymer
occur
incred
high
commit
catalysi
k
eq
sinc
forward
kinet
step
phosphoryl
transfer
k
pol
sec
gener
much
faster
correspond
revers
step
pyrophosphorolysi
k
pyro
sec
two
featur
coupl
addit
pharmacokinet
problem
drug
absorpt
metabol
nucleosid
triphosph
hinder
convent
approach
altern
strategi
take
advantag
polymeras
high
commit
catalysi
trick
enzym
use
potenti
suicid
inhibitor
trojan
hors
strategi
outlin
figur
repres
current
paradigm
design
implement
mani
nucleosid
analog
target
prokaryot
eukaryot
dna
polymeras
polymeras
provid
modifi
nucleotid
azttp
incorpor
dna
effici
natur
counterpart
dttp
incorpor
howev
modifi
nucleotid
creat
nucleic
acid
substrat
elong
thu
termin
dna
synthesi
gener
develop
effect
chaintermin
nucleotid
depend
upon
sever
featur
includ
high
catalyt
effici
incorpor
potenti
subsequ
elong
poor
excis
incorpor
select
util
polymeras
respons
pathogen
state
effect
metabol
parent
nucleosid
form
correspond
nucleosid
triphosph
follow
section
describ
success
pitfal
associ
sever
therapeuticallyrelev
nucleosid
analog
discuss
begin
analyz
develop
applic
sever
viral
dna
polymeras
inhibitor
repres
major
effort
modern
pharmaceut
scienc
virus
respons
wide
varieti
human
diseas
rang
simpl
ailment
includ
common
cold
chickenpox
cold
sore
seriou
health
threat
aquir
immun
defici
syndrom
aid
sever
acut
respiratori
syndrom
sar
cervic
cancer
addit
alarm
number
diseas
progress
multifoc
leukoencephalopathi
pml
multipl
sclerosi
may
also
link
viral
infect
univers
featur
virul
propag
viru
requir
high
level
dna
synthesi
exampl
revers
transcript
viral
singlestrand
rna
genom
human
immunodefici
viru
hiv
doublestrand
dna
catalyz
retrovir
polymeras
revers
transcriptas
rt
rnaand
dnadepend
polymeras
prime
target
antivir
drug
develop
sinc
play
essenti
role
hiv
life
cycl
date
two
distinct
type
rt
inhibitor
uniqu
pharmacodynam
behavior
develop
clinic
use
includ
nucleosid
rt
inhibitor
nonnucleosid
rt
inhibitor
nnrti
figur
compar
structur
natur
nucleosid
sever
nucleosid
analog
approv
antivir
agent
hiv
herp
simplex
viru
hsv
anoth
import
viral
target
nucleosid
analog
share
common
featur
distinguish
natur
counterpart
absenc
group
requir
subsequ
primer
elong
previous
illustr
figur
azttp
effect
chaintermin
due
simpl
replac
hydroxyl
group
azid
n
sinc
code
potenti
nucleobas
remain
ident
natur
nucleosid
bind
affin
chaintermin
azt
well
stavudin
ddc
zalcitabin
nearli
ident
natur
counterpart
howev
maxim
rate
constant
incorpor
azttp
significantli
slower
dttp
incorpor
compar
k
pol
valu
vs
sec
azttp
dttp
respect
thu
alter
ribos
moieti
appear
influenc
phosphoryl
transfer
step
andor
abil
polymeras
mediat
conform
chang
preced
kinet
step
regardless
k
pol
k
valu
modifi
nucleotid
compar
natur
counterpart
inhibit
viral
replic
via
chaintermin
corrobor
clinic
data
show
viral
load
reduct
upon
treatment
analog
acyclovir
figur
uniqu
guanin
analog
wide
use
treatment
herp
simplex
herp
zoster
shingl
infect
review
acyclovir
differ
significantli
aforement
antivir
agent
sugar
replac
openchain
structur
account
chaintermin
capabl
howev
mofic
confer
two
addit
pharmacodynam
properti
make
highli
effect
antivir
agent
first
unusu
high
select
convers
acycloguanosin
monophosph
acylogmp
virallyencod
thymidin
kinas
oppos
host
kinas
higher
activ
viral
enzym
lead
higher
concentr
acylogmp
infect
cell
oppos
healthi
unfect
cell
secondli
triphosph
form
acyclovir
acyclogtp
incorpor
effici
viral
polymeras
compar
host
enzym
two
featur
make
acyclovir
one
safest
antivir
agent
current
market
success
acyclovir
spawn
develop
number
acyclonucleosid
antivir
agent
page
limit
prohibit
thorough
discuss
analog
howev
excel
overview
uniqu
antivir
agent
provid
hewlett
et
al
despit
widespread
use
therapeut
util
nucleosid
analog
often
restrict
major
complic
includ
develop
resist
induct
advers
side
effect
resist
hivrel
nucleosid
analog
invari
develop
clinic
set
one
sever
mechan
first
convers
nucleosid
requir
triphosph
form
limit
action
host
thymidin
kinas
result
lower
plasma
concentr
may
limit
effect
second
mechan
occur
via
gener
select
point
mutat
rt
hinder
incorpor
chaintermin
effect
util
natur
nucleotid
one
exampl
mutant
caus
resist
simpl
steric
hindranc
amino
acid
side
chain
valin
ring
nucleosid
triphosph
simpl
mutat
decreas
bind
affin
chaintermin
effect
bind
natur
substrat
dttp
gener
point
mutat
also
account
third
common
mechan
resist
enhanc
enzymat
remov
chaintermin
viral
genom
via
pyrophosphorolysi
revers
polymer
advers
side
effect
aris
inher
low
select
nucleosid
analog
effect
util
either
viral
host
dna
polymeras
inhibit
dna
synthesi
case
hiv
howev
hypothes
viral
replic
would
select
inhibit
sinc
hiv
rt
possess
exonucleas
activ
remov
chain
termin
viral
genom
contrast
eukaryot
polymeras
robust
exonucleas
activ
rapidli
excis
analog
allow
replic
host
genom
hindsight
assumpt
prove
inaccur
mani
antivir
agent
slowli
excis
host
enzym
andor
rapidli
remov
viral
genom
former
case
chronic
administr
certain
nucleosid
analog
caus
side
effect
resembl
herit
mitochondri
diseas
patient
treat
one
nucleosid
analog
gener
display
phenotyp
rang
peripher
neuropathi
cardiac
skelet
muscl
myopathi
pancreat
bone
marrow
suppress
molecular
basi
side
effect
appear
link
inhibit
mitochondri
dna
replic
catalyz
pol
fact
recent
review
lee
et
al
provid
excel
descript
predict
index
correl
clinic
toxic
nucleosid
analog
probabl
chain
termin
nucleotid
incorpor
subsequ
excis
dna
pol
clear
diminut
exonucleas
proofread
human
polymeras
caus
increas
risk
toxic
howev
differ
complic
aris
viral
polymeras
effici
excis
chaintermin
viral
genom
via
pyrophosphorolysi
describ
earlier
pyrophosphorolysi
play
import
role
drug
resist
effici
remov
chain
termin
allow
rt
reiniti
viral
dna
synthesi
longterm
treatment
azt
set
mutat
includ
develop
within
activ
site
hiv
rt
confer
resist
structur
mutant
complex
chaintermin
dna
review
instrument
understand
mechan
resist
model
rt
posit
primer
two
distinct
locat
denot
prime
site
psite
nucleotidebind
site
nsite
normal
replic
rt
bind
p
site
dntp
bind
occur
nsite
phosphoryl
transfer
newli
extend
primer
transfer
nsite
psite
catalyt
cycl
continu
howev
dynam
cycl
alter
chaintermin
incorpor
absenc
chaintermin
primer
prevent
elong
thu
bind
next
correct
dntp
nsite
typic
caus
format
deadend
ternari
complex
prevent
dna
synthesi
howev
aforement
mutat
allow
rt
partit
chaintermin
primer
psite
back
nsite
movement
allow
pp
bind
subsequ
pyrophosphorolysi
excis
chaintermin
dna
synthesi
resum
although
pp
natur
substrat
excis
reaction
atp
also
act
acceptor
substrat
atp
appear
interact
directli
within
activ
site
stack
interact
purin
moieti
aromat
ring
sinc
pyrophosphorolysi
play
import
role
drug
resist
signific
effort
place
develop
molecul
inhibit
process
one
exampl
foscarnet
structur
mimic
pp
select
inhibit
bind
pyrophosph
variou
viral
dna
polymeras
foscarnet
wide
use
antivir
agent
cytomegaloviru
retin
hsv
type
infect
howev
use
hiv
therapi
limit
chronic
administr
caus
electrolyt
imbal
nephrotox
due
alter
calcium
magnesium
potassium
phosphat
level
addit
nucleosid
analog
anoth
import
class
rt
inhibitor
wide
use
treatment
hiv
infect
nonnucleosid
revers
transcriptas
inhibitor
nnrti
clear
structur
provid
figur
analog
bear
resembl
nucleosid
analog
azt
ddc
fact
class
agent
initi
identifi
potent
inhibitor
hiv
rt
high
throughput
screen
effort
rather
ration
drug
design
target
activ
site
polymeras
steadyst
inhibit
studi
determin
nnrti
efavirenz
act
uncompetit
inhibitor
low
drug
concentr
nm
result
consist
mechan
efavirenz
bind
ternari
rt
dna
dntp
complex
higher
affin
either
free
rt
rt
dna
complex
transient
kinet
studi
monitor
polymer
reveal
nnrti
block
phosphoryl
transfer
reaction
without
interf
nucleotid
bind
figur
step
nucleotideinduc
conform
chang
figur
step
instead
nnrti
bind
allow
incom
nucleosid
triphosph
bind
tightli
k
nm
nonproduct
manner
repres
one
first
exampl
small
molecul
bind
alloster
site
caus
potent
inhibit
inde
structur
analysi
reveal
nnrti
bind
hydrophob
pocket
polymeras
line
larg
hydrophob
amino
acid
includ
locat
enzym
polymeras
activ
site
surprisingli
resist
nnrti
develop
rapidli
gener
point
mutat
within
hydrophob
bind
site
exampl
recent
retrospect
cohort
studi
hivinfect
patient
treat
nevirapin
reveal
resist
isol
develop
treat
patient
within
week
furthermor
crossresist
nnrti
efavirenz
delavirdin
detect
patient
suggest
common
set
mutat
lead
resist
gener
drug
resist
aris
due
replac
larg
amino
acid
smaller
one
weaken
molecular
interact
inhibitor
rt
exampl
nevirapin
bind
weakli
mutant
wildtyp
rt
reduc
affin
reflect
increas
offrat
inhibitor
rt
dna
complex
rather
simpl
steric
hindranc
surprisingli
entravirin
new
nnrti
remain
activ
alloster
inhibitor
mutant
rt
resist
current
use
nnrti
nevirapin
combin
therapi
coadministr
multipl
drug
target
variou
patholog
pathway
strategi
wide
use
treatment
hyperprolif
diseas
hiv
fact
nucleosid
inhibitor
often
combin
nnrti
nevirapin
synergist
reduc
viral
load
vivo
particular
drug
combin
benefici
delay
onset
resist
nucleosid
analog
occur
pyrophosphorolysi
occur
sinc
bind
nnrti
alloster
site
inhibit
pyrophosphorylyt
activ
rt
reduc
bind
affin
phosphoryl
acceptor
pp
atp
well
reduc
rate
chemic
step
combin
drug
reduc
rate
drug
resist
complet
elimin
intrins
low
fidel
rt
eventu
gener
drugresist
mutant
viral
dna
synthesi
view
errorpron
process
least
one
mutat
introduc
per
round
replic
lack
fidel
caus
low
mutat
rate
consid
benefici
certain
virus
gener
select
point
mutat
critic
protein
confer
resist
howev
higher
rate
mutagenesi
reduc
viral
fit
viabil
thu
provoc
therapeut
strategi
use
promutagen
nucleosid
analog
increas
mutat
frequenc
viru
beyond
critic
threshold
capabl
support
viabil
nucleosid
analog
would
littl
effect
integr
host
genom
sinc
eukaryot
polymeras
exhibit
higher
intrins
fidel
would
prevent
analog
stabli
incorpor
dna
proofofconcept
strategi
first
demonstr
loeb
laboratori
use
figur
promutagen
nucleosid
pair
either
guanin
adenin
treatment
hivinfect
cell
promutagen
nucleosid
show
reduct
viral
replic
correl
disproportion
increas
g
substitut
isol
viral
dna
anoth
exampl
ribavirin
ribos
form
figur
use
treat
viral
infect
sar
hepat
c
promutagen
nucleosid
reduc
infect
polioviru
product
littl
coincid
induct
mutat
viral
genom
caus
misincorpor
ribavirin
opposit
c
u
studi
provid
excit
novel
therapeut
strategi
convert
perceiv
strength
viru
low
polymer
fidel
target
therapeut
intervent
despit
advanc
detect
prevent
cancer
diseas
still
remain
secondlead
caus
death
industri
nation
cancer
best
defin
hyperprolif
diseas
sinc
hallmark
patholog
malign
uncontrol
dna
synthesi
treatment
modal
vari
depend
upon
whether
cancer
solid
tumor
brain
lung
pancreat
colon
etc
hematolog
malign
leukemia
lymphoma
howev
combin
therapi
typic
employ
either
case
variou
chemotherapeut
agent
use
target
differ
biolog
pathway
respons
sustain
uncontrol
growth
cancer
one
import
class
chemotherapeut
agent
nucleosid
analog
fludarabin
cladribin
gemcitabin
cytarabin
figur
mechan
action
similar
previous
discuss
antivir
agent
azt
ribos
moieti
essenti
primer
elong
modifi
compar
natur
nucleosid
howev
major
differ
deoxyribos
sugar
replac
arabinos
anoth
modifi
sugar
moieti
simpl
replac
caus
number
pharmacodynam
effect
make
analog
effect
anticanc
agent
inhibit
dna
synthesi
via
multipl
mechan
refer
figur
exampl
fludarabin
behav
classic
chaintermin
dna
synthesi
sinc
alter
sugar
composit
make
refractori
elong
incorpor
dna
howev
fludarabin
exhibit
addit
chemotherapeut
properti
act
antimetabolit
inhibit
activ
ribonucleotid
reductas
adenosin
deaminas
two
key
enzym
involv
purin
metabol
sinc
agent
hit
multipl
target
highli
effect
singl
agent
treatment
chronic
lymphocyt
leukemia
howev
also
use
combin
chemotherapeut
agent
dna
damag
agent
cyclophosphamid
mitoxantron
glucocortcoid
steroid
dexamethason
cytarabin
figur
pyrimidin
analog
act
substrat
eukaryto
dna
rna
polymeras
exert
cytotox
effect
termin
replic
transcript
pyrimidin
analog
similar
fludarin
also
indirectli
inhibit
dna
synthesi
disrupt
proper
balanc
nucleotid
pool
inhibit
ribonucleotid
reductas
activ
decitabin
anoth
pyrimidin
analog
near
perfect
mimet
carbon
replac
nitrogen
figur
simpl
substitut
influenc
abil
properli
basepair
guanin
overt
inhibitori
effect
dna
synthesi
instead
subtl
modif
prevent
abil
nucleobas
modifi
class
dnamodfiy
enzym
known
dna
methyltransferas
influenc
transcript
rather
replic
dna
methyl
epigenet
modif
revers
regul
gene
express
without
chang
origin
dna
sequenc
gene
promot
eukaryot
express
mani
gene
invers
correl
methyl
statu
promot
region
certain
form
cancer
promot
region
critic
gene
regul
import
cellular
function
becom
hypermethyl
inappropri
epigenet
modif
lower
gene
express
reduc
intacellular
level
critic
protein
exampl
mani
sporad
colon
cancer
show
hypermethyl
gene
promot
correl
lower
express
gene
product
essenti
dna
repair
protein
reduc
level
repair
enzym
play
import
role
develop
carcinogenesi
addit
drugresist
variou
chemotherapeut
agent
temozolomid
damag
dna
howev
cell
treat
demethyl
agent
regain
express
protein
sensit
cell
cytotox
effect
certain
chemotherapeut
agent
although
use
chemotherapeut
agent
possess
rel
narrow
therapeut
window
affect
methyl
pattern
normal
cancer
cell
nucleosid
analog
import
treat
cancer
util
often
limit
doselimit
toxic
aris
due
nonselect
natur
expect
number
bodi
normal
cell
also
divid
rapidli
therefor
kill
class
chemotherapeut
agent
nonselect
kill
contribut
develop
debilit
side
effect
includ
alopecia
temporari
hair
loss
mucos
mouth
sore
anemia
reduc
red
blood
cell
number
leukopenia
reduc
white
blood
cell
number
thrombocytopenia
decreas
platelet
number
gastrointestin
symptom
nausea
vomit
diarrhea
intens
side
effect
depend
heavili
upon
dose
durat
exposur
chemotherapeut
agent
exampl
patient
treat
high
dose
fludarabin
often
develop
leukopenia
thrombocytopenia
lead
opportunist
infect
bleed
disord
result
patient
receiv
fludarabin
sometim
coadminsit
antibiot
prophylact
measur
opportunist
infect
major
disadvantag
current
arsen
nucleosid
analog
doselimit
toxic
aris
lack
select
inhibit
one
dna
polymeras
versu
anoth
unexpect
sinc
current
analog
bear
structur
ident
natur
nucleosid
thu
incorpor
opposit
templat
nucleobas
high
catalyt
effici
addit
complic
dna
polymeras
character
date
share
common
structur
featur
prohibit
use
ration
drug
design
select
target
activ
site
overal
structur
dna
polymeras
resembl
right
hand
contain
finger
palm
thumb
subdomain
palm
domain
close
conserv
structur
featur
contain
amino
acid
requir
phosphoryl
transfer
finger
domain
interact
incom
dntp
well
templat
base
thu
play
import
role
nucleotid
select
thumb
domain
play
dual
role
posit
duplex
dna
incom
dntp
well
process
transloc
polymeras
rather
directli
target
activ
site
polymeras
altern
approach
develop
nucleosid
analog
select
incorpor
opposit
modifi
damag
dna
approach
would
inhibit
promutagen
dna
synthesi
could
advantag
sever
reason
first
approach
repres
chemoprevent
strategi
gener
diseasecaus
mutat
caus
misrepl
damag
dna
would
inhibit
secondli
approach
could
use
adjunct
therapi
sensit
cancer
cell
effect
chemotherapeut
agent
damag
dna
refer
figur
step
vitro
applic
strategi
demonstr
lab
use
abas
site
model
form
dna
damag
abas
site
commonli
form
dna
lesion
result
hydrolysi
cn
bond
purin
pyrimidin
hydrolysi
occur
spontan
significantli
enhanc
dna
damag
agent
temozolomid
net
effect
hydrolysi
reaction
templat
inform
origin
present
dna
lost
caus
abas
site
highli
promutagen
despit
nontempl
natur
abas
site
dna
polymeras
preferenti
incorpor
datp
opposit
lesion
appli
inform
ration
design
seri
triphosph
mimic
core
structur
datp
figur
review
vitro
kinet
analys
reveal
analog
contain
signific
densiti
incorpor
opposit
abas
site
high
catalyt
effici
sec
valu
fold
higher
prefer
natur
substrat
datp
contrast
nonnatur
nucleotid
lack
extens
densiti
poorli
insert
opposit
abas
site
kinet
studi
demonstr
simpl
alter
surfac
area
nonnatur
nucleotid
modul
effici
incorpor
opposit
abas
site
addit
evid
certain
nonnatur
nucleotid
util
variou
dna
polymeras
effect
analog
class
one
possibl
function
finger
thumb
subdomain
conserv
amongst
dna
polymeras
subtl
differ
respect
sequenc
structur
characterist
select
inhibitor
could
develop
exploit
nuanc
develop
applic
class
nonnatur
nucleosid
open
new
avenu
toward
understand
mechan
biolog
consequ
transles
dna
synthesi
exploit
adjunct
chemotherapeut
agent
inhibit
dna
replic
remain
import
therapeut
strategi
numer
diseas
includ
viral
infect
cancer
current
arsen
agent
target
polymeras
activ
gener
base
upon
modif
moieti
nucleotid
design
prevent
elong
nucleic
acid
effect
vast
major
nucleosid
analog
display
pharmacodynam
complic
includ
intrins
lack
select
develop
drug
resist
addit
pharmacokinet
problem
convers
triphosph
form
degrad
salvag
pathway
limit
effect
howev
new
therapeut
approach
current
develop
circumv
complic
includ
develop
select
inhibitor
polymeras
involv
dna
repair
andor
transles
dna
synthesi
ddc
cbv
hydroxymethyl
guanin
acyclovir
methyl
nnrti
nonnucleosid
revers
transcriptas
inhibitor
efavirenz
trifluoromethyl
nevirapin
delavirdin
n
methanesulfonamid
entravin
amino
fludaribin
cladarabin
cytarabin
gemcitabin
decitabin
triphosph
triphosph
triphosph
triphosph
triphosph
triphosph
dna
replic
catalyz
dna
polymeras
process
polymeras
incorpor
triphosph
opposit
dna
templat
guid
incorpor
event
b
chemotherapeut
strategi
use
inhibit
dna
replic
includ
dna
damag
agent
inhibit
dna
modifi
enzym
inhibit
enzym
involv
nucleotid
metabol
nucleosid
analog
directli
inhibit
dna
polymeras
activ
kinet
mechan
rnaand
dnadepend
polymeras
individu
step
along
pathway
dna
polymer
number
identifi
abbrevi
e
polymeras
dna
n
dna
substrat
e
conform
chang
dna
polymeras
pp
inorgan
pyrophosph
dna
dna
product
dna
extend
one
nucleobas
mechan
chaintermin
nucleotid
inhibit
dna
synthesi
azttp
effect
chaintermin
due
simpl
replac
hydroxyl
group
azid
n
prevent
subsequ
primer
elong
structur
sever
nucleosid
analog
commonli
use
antivir
agent
see
text
detail
structur
variou
nonnucleosid
revers
transcriptas
inhibitor
nnrti
target
hiv
revers
transcriptas
see
text
detail
structur
sever
nucleosid
analog
wide
use
anticanc
agent
see
text
detail
structur
new
seri
show
select
incorpor
opposit
damag
versu
undamag
dna
